Roiver Score™ for
SUPNSupernus Pharmaceuticals, Inc.
Based on fundamentals through 12/31/2025.
As of December 31, 2025, Supernus Pharmaceuticals, Inc. (SUPN) scores 2/100 (Weak) on the Roiver Score — a transparent quality composite. Its strongest area is cash quality; its weakest is stability. The score measures business quality, not timing — it's a signal, not a recommendation.
No black box
Roiver Score is a transparent 0–100 quality composite. Five components, each 0–20: profitability, capital structure, cash quality, valuation, and stability. Inspired by Piotroski's F-Score, Altman's Z-Score, and the Buffett/Munger framework on quality compounders at fair prices. Read the full methodology →
Frequently asked about SUPN
What is SUPN's Roiver Score?
Supernus Pharmaceuticals, Inc. scores 2 out of 100 (Weak) as of December 31, 2025, based on fundamentals.
How is the Roiver Score for SUPN calculated?
It sums five 0–20 components — profitability, capital structure, cash quality, valuation, and stability — into a transparent 0–100 composite. The full methodology is published.
Is SUPN a good quality stock?
On quality, SUPN rates "Weak" (2/100). Its strongest driver is cash quality and its weakest is stability. Quality is one input to a decision, not a buy/sell call.
Embed on your site
Drop this iframe into a Substack, blog post, or notion page. Updates automatically as fundamentals change.
<iframe src="https://roiver.com/embed/score/SUPN" width="640" height="280" frameborder="0" style="border:0;border-radius:16px;overflow:hidden" loading="lazy"></iframe>
Get SUPN's Score in your inbox
A free weekly digest of quality scores and what changed. No account needed.
Educational use only. Roiver Score is a quality signal, not a recommendation.